PANECTYL 5 MG
TRIMEPRAZINE (TRIMEPRAZINE TARTRATE) : 5 MG · DIN 01926292 · SEARCHLIGHT PHARMA INC
Health Canada status: CANCELLED POST MARKET
What is PANECTYL?
PANECTYL 5 MG contains TRIMEPRAZINE (TRIMEPRAZINE TARTRATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 01926292, held by SEARCHLIGHT PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Oct-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PANECTYL used for?
Pruritus (neurodermatitis, eczema, urticaria, insect bites, etc.) and cough of various etiologies (upper respiratory tract conditions, asthma, hay fever).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01926292 |
|---|---|
| Brand name | PANECTYL |
| Generic / active ingredient | TRIMEPRAZINE (TRIMEPRAZINE TARTRATE) : 5 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | R06AD01 ALIMEMAZINE |
| AHFS class | 04:04.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Oct-2024 |
| Original market date | 1959-12-31 00:00:00 |
How is it administered?
Adults: 2.5-5 mg twice daily after meals plus 5 mg at bedtime. Children (2-12): 2.5-5 mg at bedtime; max 15 mg/day. Hospitalized adults: up to 80 mg/day for severe pruritus.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (standard manufacturer standard mentioned). Light-sensitive crystalline powder.
How is it supplied?
Bottles of 100 tablets.
Contraindications
CNS depression (alcohol, barbiturates, narcotics); history of blood dyscrasias or severe phenothiazine allergy; children under 2 years of age.
Warnings and precautions
May impair mental alertness (driving); risk of cardiac arrhythmias/QT prolongation; risk of Neuroleptic Malignant Syndrome (NMS) in overdose. Do not exceed recommended dose.
What can be used instead?
Other Canadian products sharing ATC code R06AD01 ALIMEMAZINE. 0 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PANECTYL | 2.5 MG | TABLET | SEARCHLIGHT PHARMA INC | CANCELLED POST MARKET | DIN 01926306 |
| PANECTYL 2.5 LIQ 2.5MG/5ML | 2.5 MG / 5 ML | LIQUID | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 01926446 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.